MeiraGTx Holdings plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MGTX research report →
Range $16 – $26
Price Chart
About the company
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
- CEO
- Alexandria Forbes
- IPO
- 2018
- Employees
- 393
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on MGTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $982.59M
- P/E
- 13.96
- Fwd P/E
- 35.37
- PEG
- 0.07
- P/S
- 2.47
- P/B
- 4.50
- EV/EBITDA
- 3.66
- Div Yield
- 0.00%
- Gross Margin
- 97.19%
- Op Margin
- 46.30%
- Net Margin
- 19.87%
- ROE
- 284.38%
- ROIC
- 52.45%
Latest fiscal year · YoY change
- Revenue
- $81.39M+144.6%
- Gross Profit
- $76.55M+706.8%
- Op Income
- $-105,968,000
- Net Income
- $-114,201,000+22.7%
- EPS
- $-1.42+33.0%
- OCF Growth
- +55.6%
- FCF Growth
- +54.1%
- 52W High
- $15.35
- 52W Low
- $6.62
- 50D MA
- $12.86
- 200D MA
- $10.11
- Beta
- 1.27
- RSI (14)
- 29
- Avg Volume
- 790.64K
No earnings-call transcripts are available for MGTX yet.
- Free Float
- 75.7%
- Shares Outstanding
- 92.61M
- Float Shares
- 70.14M
of shares held by institutions
162 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sanofi | 12.20M | 0 |
| Perceptive Advisors LLC | 10.79M | ▲ 460.56K |
| Rubric Capital Management LP | 9.10M | ▲ 2.10M |
| Johnson & Johnson | 6.64M | 0 |
| Blackrock, Inc. | 4.76M | ▲ 1.59M |
| Adage Capital Partners Gp, L.L.C. | 4.40M | ▲ 400.00K |
| Opaleye Management Inc. | 3.55M | ▲ 1.43M |
| Millennium Management LLC | 2.97M | ▼ 493.95K |
| 683 Capital Management, LLC | 2.30M | ▼ 150.00K |
| Woodline Partners LP | 1.50M | ▲ 1.20M |
| State Street Corp | 1.39M | ▲ 639.84K |
| Morgan Stanley | 1.31M | ▼ 277.24K |
Held by 152 ETFs
Biggest fund positions in MGTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 26 | SEBULSKY ALAN | other | 100,000 |
| Sep 23, 26 | SEBULSKY ALAN | other | 0 |
| Aug 18, 26 | Forbes Alexandria | sell | 62,000 |
| Jul 21, 26 | Giroux Richard | sell | 56,000 |
| Jul 7, 26 | Naylor Stuart | sell | 2,547 |
| Jul 7, 26 | Naylor Stuart | sell | 25,112 |
| Jun 25, 26 | Zeldin Robert K | other | 100,000 |
| Jun 25, 26 | Wollin Robert J | other | 100,000 |
| Jun 25, 26 | Naylor Stuart | other | 70,000 |
| Jun 25, 26 | Giroux Richard | other | 980,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MGTX coverage
Recent articles, reports, and earnings notes.
No research on MGTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MGTX report →Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR)
defenseworld.net · Sep 30
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
globenewswire.com · Sep 23
Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX)
defenseworld.net · Sep 11
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide
gurufocus.com · Aug 26
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
prnewswire.com · Aug 26
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
zacks.com · Aug 13
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
globenewswire.com · Aug 13
Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
prnewswire.com · Aug 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.